Dossier assessment
Sodium thiosulfate (prevention of ototoxicity induced by cisplatin chemotherapy in solid tumours) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Sodium thiosulfate (prevention of ototoxicity induced by cisplatin chemotherapy in solid tumours) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Sodium thiosulfate (prevention of ototoxicity induced by cisplatin chemotherapy in solid tumours) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Patients 1 month to < 18 years of age with localized, non-metastatic, solid tumours with indication for the prevention of ototoxicity induced by cisplatin chemotherapy
- Patients with hepatoblastoma: hint of minor added benefit
- Patients with other solid tumours: added benefit not proven
Project details
- Project no.
- A25-15
- Commission
- Commission awarded on 03.02.2025 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A25-15_en